By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AEterna Zentaris 

1405 Boul Du Parc-technologique

Quebec  Quebec  G1P 4P5  Canada
Phone: 418-652-8525 Fax: 418-652-0881


Company News
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015 6:51:02 AM
AEterna Zentaris (AEZS) Announces Proposed Public Offering Of Common Shares And Warrants 3/6/2015 6:40:04 AM
AEterna Zentaris (AEZS) To Present At Upcoming Biotech Showcase Conference In San Francisco 1/6/2015 9:36:23 AM
AEterna Zentaris (AEZS): Final Data For Phase 1 Portion Of Ongoing Phase 1/2 Trial With Zoptarelin Doxorubicin In Prostate Cancer Published In Clinical Cancer Research 12/29/2014 7:42:34 AM
AEterna Zentaris (AEZS) Receives Notification From NASDAQ Relating To Minimum Bid Price 12/19/2014 8:47:29 AM
AEterna Zentaris (AEZS) And Sinopharm A-Think Sign Master Collaboration Agreement For Zoptarelin Doxorubicin In China 12/1/2014 6:24:06 AM
AEterna Zentaris (AEZS) Adds Hollings Cancer Center To Multi-National Phase 3 Trial In Endometrial Cancer 11/20/2014 9:54:39 AM
FDA Issues Complete Response Letter For AEterna Zentaris (AEZS)' Macrilen™ NDA In Adult Growth Hormone Deficiency 11/6/2014 8:25:29 AM
Despite Restructuring, AEterna Zentaris (AEZS) Plummets On FDA Rejection 11/6/2014 7:00:15 AM
AEterna Zentaris (AEZS) Reports Third Quarter 2014 Financial And Operating Results 11/5/2014 7:52:46 AM